For gene therapy, in vivo delivery of plasmid DNA offers an alternative to viral delivery methods. Since the efficiency of plasmid delivery to tissues is generally lower than viral delivery, several methods have been introduced to augment in vivo plasmid delivery, including in vivo electroporation, which has been used in phase II clinical trials for the delivery of chemotherapeutic agents to cancers.
For gene therapy, in vivo delivery of plasmid DNA offers an alternative to viral delivery methods. Since the efficiency of plasmid delivery to tissues is generally lower than viral delivery, several methods have been introduced to augment in vivo plasmid delivery, including in vivo electroporation, which has been used in phase II clinical trials for the delivery of chemotherapeutic agents to cancers. 1, 2 A number of preclinical studies have been performed demonstrating that this technique also enhances plasmid delivery and expression of both reporter and therapeutic genes or cDNAs to many tissues. 3 Electroporation delivery has been performed to a number of normal tissues including skin, [4] [5] [6] [7] liver, 8, 9 and testes, 10 although since skeletal muscle injected with plasmid DNA alone expresses reporter genes, 11 much of the focus of in vivo electroporation has been on muscle delivery. Both intramuscular and systemic plasmid expression are significantly augmented by the addition of electric pulses. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Electroporation directly into tumors also enhances plasmid expression. This has been demonstrated using reporter genes in rat brain tumors, 24 mouse melanomas, 25 mouse mammary tumors, 26 and rat liver tumors. 27 Therapeutic responses have also been described, including human monocyte chemoattractant protein-1 in rat brain tumors, 24 a dominant negative Stat3 variant in mouse melanomas, 28 ine kinase in subcutaneously inoculated colon adenocarcinomas, 29 and IL12 in subcutaneously implanted hepatocelluar carcinomas, 30 subcutaneously implanted colon carcinomas, 31 or IL12 and IL18 in mouse melanomas. 32 The combination of electrochemotherapy and cytokine plasmid delivery by electroporation into mouse melanomas prevents tumor recurrence and induces long-term antitumor immunity. 33 Intramuscular delivery of plasmids encoding tumor antigens inhibits melanoma growth, 34 while delivery of IFN␣ plasmid inhibits growth of squamous cell carcinomas. 35 In the experiments described here, the intratumor delivery of plasmid DNA into B16 mouse melanomas by two different electroporation protocols was compared. These two types of electroporation conditions had been demonstrated previously for delivery of plasmid DNA into mouse melanomas. These protocols differed significantly in pulse length, field strength, and the electrode used for delivery ( Figure 1 ). Relative reporter gene expression after intratumor plasmid delivery was first compared. Both protocols resulted in significantly increased plasmid expression, although EP1 increased reporter expression 21-fold, while EP2 increased expression 42-fold.
The effect on tumor growth of electroporation alone, luciferase plasmid injection alone, or the combination was observed in B16 mouse melanomas (Figure 2a ). Tumors were treated as indicated on day 0, when they were approximately 4 mm in diameter, day 3, and day 7. Application of pulses after injection of saline only or injection of 100 g plasmid DNA without pulses only minimally slowed tumor growth. Interestingly, when plasmid injection was combined with intratumor electroporation, a significant number of complete tumor regressions were observed when using one, but not the other electroporation protocol, even though these two delivery methods resulted in only a two-fold difference in reporter expression. This regression occurred after injection of plasmid DNA followed by electroporation protocol EP2, but not after the application of electroporation protocol EP1. The observed regression was longlived and occurred in a significant number of animals (P Ͻ 0.05, Figure 2b ). This effect might have been related to the amount of DNA delivered intracellularly for two reasons. First, it was associated with the electroporation protocol that resulted in the higher level of plasmid expression as demonstrated by reporter gene expression (Figure 1) . Second, this effect displayed a dependence on DNA concentration, since sustained complete regression occurred in 42% of tumors electroporated with 50 g plasmid DNA, and this percentage increased to 83% in tumors electroporated with 100 g plasmid DNA.
Because of this interesting observation, the remaining experiments focused on DNA delivery using electroporation protocol EP2. This antitumor effect was neither plasmid-dependent nor dependent on the presence of eukaryotic coding sequences. When melanomas were treated three times with electroporation with the plasmid pUC18, the effect on tumor growth was confirmed (Figure 3a) . Figure 1 on days 0, 3 3 
. Each individual tumor volume was normalized to its volume on day 0, the first day of treatment. (a) Tumor volumes and (b)
tumor-free animals after delivery of plasmid DNA (VR1255) with electroporation. ᭺, no treatment; +, injection of 100 g pDNA only; ᭛, saline injection followed electroporation protocol EP1; ᮀ, saline injection followed by electroporation protocol EP2; ᭜, injection of 100 g pDNA followed by EP1;̆, injection of 50 g pDNA followed by EP2, , injection of 100 g pDNA followed by EP2 (n = 6-7 mice).
The regression induced by this treatment was also long-lived (Figure 3b) , with approximately 70% of mice surviving tumor-free until challenge. For the challenge, all mice in the experiments described which remained tumor-free were injected along with naive controls on the opposite flank with 5 × 10 5 B16 cells at day 56, 63, or 74 and monitored for another 50 days. While visible tumors appeared within 10 days in all the naive control mice, 70% (12 of 17) of mice did not grow challenge tumors and so may have developed immunity to B16 cells.
The sustained complete regression observed was also dependent on the number of treatments applied. When only a single treatment of 100 g plasmid DNA followed by electroporation was used, five of six tumors completely regressed, but four of these tumors recurred by day 14 (data not shown). The remaining tumor did not recur, but the mouse succumbed to subcutaneous challenge with B16 melanoma cells.
Since this effect was not dependent on expression of a therapeutic protein, it might have been due to a response to the bacterially derived DNA itself. In vertebrates, the dinucleotide CpG occurs at about one fifth the expected frequency and 60-90% of those motifs are altered to 5'methylcytosine. 38 Unmethylated bacterial CpGs act as a signal for innate immunity in mammals. The immunostimulatory effect of unmethylated CpGs can be observed after uptake of bacterial genomic DNA, oligonucleotides, 39 or plasmid DNA. 40 pUC18 contains 156 copies of the dinucleotide CpG, including 20 copies of a six base immunostimulatory consensus sequence. 41 Immunostimulatory DNA has been described as an anticancer immune adjuvant, originally with Mycobacterium bovis genomic DNA. 42, 43 When CpG motif oligonucleotides are injected with a lymphoma surface antigen, a specific antilymphoma immune response is generated. 44 When the animals were challenged with lymphoma cells, survival improved when compared with control mice. The addition of treatment with soluble GM-CSF increased this survival. 45 Intravenous injection of lipid-CpG motif plasmid DNA complexes reduced the lung tumor burden in mice injected 3 days before treatment with MCA-205 fibrosarcoma, B16.F10 melanoma, and CT26 colon carcinoma cells. 46 To explore this antitumor effect, tumors were excised and examined histologically 24 h after treatment, when most tumors began regressing (Figure 4) . Untreated tumors exhibited a few inflammatory cells. Injection of DNA alone induced 5-20% necrosis and tumors were surrounded by a mixed inflammatory infiltrate. This is similar to the effect observed after muscle injection of plasmid DNA. 47 Injection of saline followed by electroporation resulted in skin burning associated with 10-50% apoptotic cells with areas of necrosis, and moderate infiltration of PMNs, macrophages, and lymphocytes. With injection of plasmid DNA followed by pulsing (Figure 5 ), the skin was again burned, but apoptosis increased to 80-100% of cells. Apoptosis was detected by TUNEL assay and semiquantitatively quantified as the percentage of apoptotic tumor cells related to the total number of tumor cells. The apoptotic tumor cells were clearly identified by their dark brown nuclei. Some nuclear chromatin condensation and/or fragmentation was also visible on the H&E stain (Figure 5a-d) . The tumor became very congested and a strong infiltrate containing PMNs, macrophages, and some lymphocytes was observed. This indicated that this tumor regression might be due not only to induction of apoptosis, but also to a concomitant immune response. The presence of marked macrophagic and lymphocytic infiltration around and within the tumors exhibiting complete response supports this view. Furthermore, while some apoptosis was induced by pulses alone, pulses alone were not an effective antitumor therapy ( Figure  2a and b) . Combination with plasmid DNA was required.
Future experiments will confirm whether this anti- tumor effect is due to the immune response to CpG motif DNA or to some other factor. In addition, the observed induction of apoptosis will be explored.
